$17.59—Stale · unknown old
NASDAQ • Last print unknown ago
$17.59—Stale · unknown old
Zealand Pharma A/S specializes in developing peptide-based therapeutics, primarily targeting diabetes and rare diseases. The company has a strong pipeline, including the recently launched Zegalogue for hypoglycemia, which positions it favorably in the competitive biotech landscape.
Zealand Pharma generates revenue primarily through the sale of its proprietary drug Zegalogue, which is used to treat severe hypoglycemia in diabetes patients. The company benefits from high gross margins of 59.4%, although it currently operates at a significant loss due to high R&D expenditures.
Regulatory approvals for new drugs in the pipeline, particularly for diabetes and rare diseases
Sales growth of Zegalogue and any new product launches
Partnerships or licensing agreements with larger pharmaceutical companies
Clinical trial results for pipeline candidates
Regulatory changes that could impact drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors in the diabetes treatment space
Potential for generic competition affecting Zegalogue's market share
High cash burn rate leading to potential liquidity issues if revenue growth does not accelerate
Dependence on a single product for revenue generation
moderate - The biotech sector can be sensitive to economic cycles, particularly in terms of healthcare spending and insurance reimbursement policies.
Higher interest rates may increase the cost of capital for Zealand Pharma, impacting its ability to fund ongoing R&D projects and operational expenses.
minimal - The company has a low debt-to-equity ratio of 0.02, indicating limited reliance on external financing.
growth - Investors looking for high-risk, high-reward opportunities in biotech with potential for significant upside from successful drug development.
high - The stock is likely to exhibit high volatility due to the binary nature of clinical trial results and regulatory approvals.